Jeffery Diberto
Director of Assay Development and co-founder at EvE Bio
Data updated
Research Footprint
Jeffery Diberto appears in 5 tracked papers (2020–2025), most studied alongside LSD, Psilocybin and Mescaline, across Depressive Disorders, Anxiety Disorders and Headache Disorders (Cluster & Migraine).
Most-cited paper: Structure of a Hallucinogen-Activated Gq-Coupled 5-HT2A Serotonin Receptor (492 citations).
Frequent co-authors: Bryan Roth, Kuglae Kim and David Nichols.
Background & Research
Jeffery DiBerto is a former graduate researcher in Bryan Roth’s lab at the University of North Carolina at Chapel Hill, where he studied GPCR pharmacology with a focus on opioid and serotonin receptors. He co-authored multiple influential papers in Cell, Nature, and Nature Communications on psychedelic drug action, 5-HT2A receptor biology, and related therapeutic mechanisms. He is now listed as Director of Assay Development and co-founder at EvE Bio.
Key Impact
He is a key experimental pharmacology researcher in psychedelic science, contributing to landmark work on 5-HT2A receptor structure, engineered mouse models, and receptor-docking studies linked to antidepressant effects.
Collaboration Network
4 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Jeffery Diberto is associated with.
EvE Bio
University of North Carolina at Chapel Hill School of Medicine
The University of North Carolina at Chapel Hill School of Medicine (UNC School of Medicine) is the medical school of the University of North Carolina at Chapel Hill. It provides MD and graduate medical education, conducts biomedical research, and delivers clinical care through UNC Health and UNC Medical Center.
View stakeholder →